Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories - Université de Lorraine Access content directly
Journal Articles Journal of the American College of Cardiology Year : 2023

Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories

Abstract

BACKGROUND Empagliflozin reduces the risk of major heart failure outcomes in heart failure with reduced or preserved ejection fraction. OBJECTIVES The goal of this study was to evaluate the effect of empagliflozin across the spectrum of chronic kidney disease in a pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced or Preserved Ejection Fraction, respectively). METHODS A total of 9,718 patients were grouped into Kidney Disease Improving Global Outcomes (KDIGO) categories based on estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio into low-, moderate-, high-, and very-high-risk categories, comprising 32.0%, 29.1%, 21.9%, and 17.0% of the participants, respectively. RESULTS In the placebo arm, when compared with lower risk categories, patients at higher risk experienced a slower rate of decline in eGFR, but a higher risk of a composite kidney event. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalizations similarly in all KDIGO categories (HR: 0.81; 95% CI: 0.66-1.01 for low-; HR: 0.63; 95% CI: 0.52-0.76 for moderate-; HR: 0.82; 95% CI: 0.68-0.98 for high-; and HR: 0.84; 95% CI: 0.71-1.01 for veryhigh-risk groups; P trend ¼ 0.30). Empagliflozin reduced the rate of decline in eGFR whether it was estimated by chronic slope, total slope, or unconfounded slope. When compared with the unconfounded slope, the magnitude of the effect on chronic slope was larger, and the effect on total slope was smaller. In EMPEROR-Reduced, patients at lowest risk experienced the largest effect of empagliflozin on eGFR slope; this pattern was not observed in EMPEROR-Preserved. CONCLUSIONS The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.
Fichier principal
Vignette du fichier
1-s2.0-S0735109723050805-main.pdf (1.74 Mo) Télécharger le fichier
1-s2.0-S0735109723050805-mmc1.docx (4.8 Mo) Télécharger le fichier
1-s2.0-S0735109723050805-mmc1.pdf (3.25 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives

Dates and versions

hal-04094627 , version 1 (11-05-2023)

Identifiers

Cite

Javed Butler, Milton Packer, Tariq Jamal Siddiqi, Michael Böhm, Martina Brueckmann, et al.. Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. Journal of the American College of Cardiology, 2023, 81 (19), pp.1902-1914. ⟨10.1016/j.jacc.2023.03.390⟩. ⟨hal-04094627⟩
17 View
38 Download

Altmetric

Share

Gmail Facebook X LinkedIn More